ArticleBMJ open2019

To what degree are review outcomes aligned for new active substances (NASs) between the European Medicines Agency and the US Food and Drug Administration? A comparison based on publicly available information for NASs initially approved in the time period 2014 to 2016.

Thomas Christian Kühler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.